It was during the XXIX Annual Meeting of the Pediatric Hematology and Oncology Society that BIOJAM once again awarded the BIOJAM INNOVATE Award in the field of Pediatric Oncological Hematology.
Although this is an award that aims to stimulate the study and development of new and innovative therapies, as well as better access to medical care, BIOJAM Pharmaceuticals believes that it is important not to forget the work of the Society, which not only aims to "promote research in Haematology and Paediatric Oncology, the standardisation of therapeutic protocols between the various National Centres and participation in cooperative studies", but also to "promote solidarity and strengthen ties between its members, representing them nationally and internationally".
Segundo Carlos Monteiro, CEO da Biojam Holding Group, “o Prémio BIOJAM INOVAR foi desenhado para motivar publicações, artigos científicos e outros, mas também pretende destacar a dedicação de todos os seus profissionais em prol de melhores cuidados para os doentes. Depois de uns anos difíceis de pandemia, entendemos atribuir à Sociedade Portuguesa Hematologia e Oncologia Pediátrica o Prémio BIOJAM pela dedicação de todos os seus profissionais aos doentes oncológicos pediátricos na promoção da sua recuperação e qualidade de vida”.
The annual meeting of the Paediatric Haematology and Oncology Society brought together some of the country's leading specialists in the field of haematology and oncology of children and adolescents, as well as around 100 health professionals.
At this meeting, organised by the Society of Paediatric Haematology and Oncology and during which current and diverse topics such as "Referred Haematological Pathology", "Hepatoblastomas", "Transplantation and Gene Therapy", "Social Integration", among others, were debated, BIOJAM, as a partner in promoting research in favour of better medical care for patients, awarded the Prize, maintaining its commitment to continuing to support and encourage the production and publication of studies.
As a leader in the treatment of Acute Lymphoblastic Leukaemia for the Iberian market, BIOJAM HG has been working together with Research Centres and Medical Societies to bring innovation to the market, particularly in the differentiated form of administration of the therapies, making them easier to administer. Thus, in addition to the drug for acute lymphoblastic leukaemia, the affected population of which is mainly children and young adults and therefore needs the dosage of the drug adapted to their body weight, research has focused on other oncological pathologies where the target populations need treatment doses that are properly adapted to their needs, and so the main objective has been to enable precise and easy treatment for these populations where the normal oral solid forms are not a solution.
Source: Multicom
